Precigen Inc. shares reached a new 52-week high of $7.74 USD on Thursday. The biotechnology company specializes in developing gene and cell therapies.
The stock has delivered a 78% return year-to-date. Market gains over the past six months have reached 110%.
Analysts predict Precigen will achieve profitability this year. This forecast represents a significant turnaround for the company, which remained unprofitable over the last 12 months.